Evidence map›Paper›PMID 40458003›Full record

ArticleCancer medicine2025

Tregs at Diagnosis as a Potential Biomarker for Predicting High-Risk Functionality in Newly Diagnosed Multiple Myeloma.

Qiaolin Zhou, Fang Xu, Jingjing Wen, Jing Yue, Ya Zhang, Lijun Du, Kun Kou, Jing Su, Yiping Liu, Xiaogong Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qiaolin ZhouHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.ORCID https://orcid.org/0000-0003-0022-0567
Fang XuHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.ORCID https://orcid.org/0000-0002-6731-1116
Jingjing WenHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.ORCID https://orcid.org/0000-0002-6994-9025
Jing YueHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.ORCID https://orcid.org/0000-0003-3557-2538
Ya ZhangHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.ORCID https://orcid.org/0000-0002-0426-333X
Lijun DuHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.ORCID https://orcid.org/0000-0002-4265-944X
Kun KouHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Jing SuHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Yiping LiuHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Xiaogong LiangHematology Department, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.ORCID https://orcid.org/0000-0003-3429-7562

Funding

Mianyang Central Hospital Clinical Research Fund 2024LC003the Medicine Association of Sichuan Province S2024080
6 · The paper itself

Abstract

objectiveThis study investigated the role of regulatory T cells (Tregs) in newly diagnosed multiple myeloma (NDMM) patients, particularly in relation to early relapse and prognosis.

methodsThe analysis included clinical data from 70 NDMM patients, with Tregs measured at diagnosis. Early relapse was defined as relapse within 18 months (ER18), and posttransplant survival extending beyond 12 months. Functional high risk (FHR) was evaluated based on this criterion.

resultsFor the overall cohort, the median progression-free survival (PFS) and overall survival (OS) were not reached, but in the ER18 cohort, median OS was 24.8 months and median PFS was 10.8 months. Key factors linked to early relapse included elevated serum creatinine levels (> 156 μmol/L), presence of extramedullary disease, and lower percentage of Tregs at diagnosis. Multivariate analysis revealed that extramedullary disease and lower percentage of Tregs were significant predictors of early relapse. Factors such as age, elevated creatinine, extramedullary disease, and lower percentage of Tregs were associated with poorer PFS. Further analysis confirmed that extramedullary lesions, elevated creatinine, and lower percentage of Tregs significantly influenced PFS.

conclusionOverall, Tregs at diagnosis were found to be important for predicting early relapse and progression-free survival, highlighting their potential as a biomarker for functional high risk in multiple myeloma.

Indexed as

Biomarkers, TumorMultiple MyelomaNeoplasm Recurrence, LocalT-Lymphocytes, RegulatoryAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRisk FactorsBiomarkers, Tumorbiomarkerearly relapsefunctional high riskmultiple myelomanewly diagnosedprognosisTreg

Identifiers

PMID40458003
PMCPMC12130636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.